925 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
4 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
6 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
7 Recruiting Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Condition: Small Cell Lung Cancer
Intervention: Drug: G1T28 + Topotecan
8 Not yet recruiting Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
9 Not yet recruiting Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Condition: ALK-positive Non-small Cell Lung Cancer
Interventions: Drug: Ceritinib;   Radiation: Stereotactic ablative body radiation
10 Recruiting Endu Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Endostar;   Drug: Changchun marina;   Drug: cisplatin;   Drug: Taxol;   Drug: parapl
11 Not yet recruiting LIquid BIopsies in Lung Cancer (LIBIL)
Condition: Carcinoma, Non-small Cell Lung
Intervention:
12 Not yet recruiting Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
Condition: ALK-positive Advanced NSCLC
Interventions: Drug: Crizotinib;   Drug: Pembrolizumab
13 Not yet recruiting AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Condition: Stage IB-IIIA Non-small Cell Lung Carcinoma, With a Centrally Confirmed, Common Sensitising EGFR Mutations
Interventions: Drug: AZD9291 80 mg/40 mg;   Drug: Placebo AZD9291 80 mg/40 mg
14 Recruiting Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Device: PET scan imaging
15 Recruiting Docetaxel + Plinabulin vs Docetaxel as 2nd-Line Chemo in Patients With Advanced NSCLC With >1 Large Lung Lesion
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Plinabulin (DP);   Drug: Docetaxel (D)
16 Not yet recruiting Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Other: Placebo
17 Recruiting AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Conditions: Lung Cancer;   Targeted Therapy
Intervention: Drug: AZD9291
18 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
19 Not yet recruiting Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Drug: Selumetinib
20 Not yet recruiting Echocardiography for RILI Prediction
Condition: NSCLC
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years